TYRA BIOSCIENCES INC

TYRANASDAQ

🏆 #1923 by market capEarnings Nov 4US Equity

$25.16▼ $0.02 (−0.08%)

Live

1h▼ 1.2%

24h▼ 0.1%

7d▼ 2.1%

14d▼ 18.9%

30d▼ 23.1%

1y▲ 137.6%

🏦Market Cap

$1.50B

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $24.91 – $25.35
52-Week Range: $9.96 – $40.65
Volume: $2.22B
Avg Volume: $2.53B
Shares Outstanding: 59.7M
Next Earnings: Oct 9, 2026

Fundamentals Snapshot

Annual Revenue: $123M
Last Q Revenue: $32M
P/E Ratio: -10.5
P/S Ratio: 0.0x
EPS (TTM): $-2.25
Dividend Yield: 0.00%

Why Investors Own TYRA

✓High-growth profile — revenue up +55.9% YoY with expanding US Equity exposure.
✓Healthy economics — 68% gross margin and 27% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$123M▲ +49.0% YoY

Gross Margin (TTM)

68.3%▲ +3.7% YoY

Operating Income (TTM)

$30M▲ +49.0% YoY

Free Cash Flow (TTM)

$34M▲ +49.0% YoY

About TYRA BIOSCIENCES INC

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

🦦